Not totally related to the quote below, but has me wondering how much the pressure on soft money researchers to pursue “novel” interventions that target big populations leads to these pre-disease definitions. Maybe not as avaricious in intent as drug makers, but maybe same end results?
Not totally related to the quote below, but has me wondering how much the pressure on soft money researchers to pursue “novel” interventions that target big populations leads to these pre-disease definitions. Maybe not as avaricious in intent as drug makers, but maybe same end results?